Cardiovascular Disease Management

Introduction to Asymptomatic PAD Management

• The European Society of Cardiology recommends against systematically treating patients with asymptomatic PAD without any sign of clinically relevant ASCVD with antiplatelet drugs 1
• Trials evaluating antiplatelet agents in asymptomatic patients with mild decrements in ABI failed to show benefit for major adverse cardiac events (MACE) or revascularization 2

Asymptomatic Patients with PAD

• The benefits of aspirin in patients with asymptomatic peripheral artery disease are not well established (Class IIb, Level of Evidence: B) 3, 4
• Aspirin (75-100 mg) for primary prevention may be considered in patients with asymptomatic PAD and diabetes mellitus, in the absence of contraindications (Class IIb) 1

Asymptomatic Carotid Stenosis Management

• In patients with asymptomatic >50% carotid stenosis, long-term antiplatelet therapy (commonly low-dose aspirin) should be considered if bleeding risk is low (Class IIa, Level C) 1

Aspirin Therapy

• The optimal dose of aspirin is 75-100 mg daily 1, 3
• Aspirin therapy is recommended at a dose of 75-162 mg daily for symptomatic patients 3, 4
• Aspirin therapy should be considered in patients with high-risk features, including diabetes mellitus, significant carotid stenosis (>50%), or high coronary artery calcium score (≥100) 1
• Aspirin therapy is not recommended in people under 30 years of age due to lack of evidence of benefit, and is contraindicated in patients under 21 years because of the risk of Reye's syndrome 5, 6, 7, 8
• Aspirin therapy is generally not recommended for diabetic patients over 70 years, as the bleeding risk may outweigh the benefits 9

Primary Prevention

• For primary prevention, aspirin should only be considered when the 10-year cardiovascular risk is sufficiently high (>5-10%), according to the American Diabetes Association 8, 7, 9
• The European Society of Cardiology guidelines emphasize that aspirin for primary prevention should be based on cardiovascular risk assessment rather than simply having diabetes 10
• Aspirin therapy offers a specific benefit for women with diabetes, as noted in the Women's Health Study, with a reduction in cardiovascular events 11

Secondary Prevention

• The American Diabetes Association strongly recommends aspirin therapy for all diabetic patients with documented atherosclerotic cardiovascular disease, as the benefit clearly outweighs the bleeding risk 12
• Aspirin therapy is recommended for secondary prevention in diabetic patients with established ASCVD, as it provides a clear benefit in reducing cardiovascular events 9
• Aspirin 81mg daily is recommended for secondary prevention in patients with established atherosclerotic cardiovascular disease after acute myocardial infarction (AMI) by the American College of Cardiology 13
• Aspirin 81mg daily is indicated for patients after coronary stent placement (bare-metal or drug-eluting) 14

Bleeding Risk Assessment and Management

• Even low-dose aspirin approximately doubles the risk of major extracranial bleeding, according to the European Heart Journal 15
• Bleeding risk factors to assess in diabetic patients include history of GI bleeding or peptic ulcer disease, concurrent use of anticoagulants or NSAIDs, uncontrolled hypertension, and renal disease or anemia 16
• For patients at higher risk of GI bleeding who require aspirin therapy, consider adding a proton pump inhibitor to reduce the risk of bleeding 9, 17, 16, 18, 12, 19, 20
• Regular reassessment of cardiovascular and bleeding risk is necessary 17, 16, 18, 12, 19

Recommended Aspirin Doses

Comorbid Condition Management

• Individualized blood pressure targets with a systolic blood pressure goal of <130 mmHg if well tolerated are recommended by the European Society of Cardiology 10
• Consideration of ACE inhibitors or ARBs as first-line therapy in diabetic hypertension is recommended by the American Diabetes Association 8
• Uncontrolled hypertension may attenuate cardiovascular benefits of aspirin, as stated by the American Family Physician 16
• Optimization of diabetes management with appropriate medication and lifestyle changes, and consideration of newer agents with cardiovascular benefits if appropriate, is recommended by the American Diabetes Association 8
• Statin therapy should be considered based on cardiovascular risk assessment, according to the American College of Cardiology 22
• Target low-density lipoprotein cholesterol levels based on risk stratification, as recommended by the European Society of Cardiology 10